\ Test
ASX Linkedin Twitter               




Presentation Title Conference Date
Clinical evaluation of a novel oncolytic immunotherapy agent, CAVATAK® in combination with immune checkpoint therapy in advanced cancer patients 2018 International Oncolytic Virus Conference (IOVC) – 11th Meeting, Oxford, United Kingdom  10 April 2018



Extended Investor Presentation* – January 2018

* Investor Presentation supplemented with previously released clinical and scientific information

© Viralytics Limited 2021